skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

February 28, 2018 is the eleventh international #Rare Disease Day.  This day is designed to raise awareness about rare diseases and their impact on patients' lives to public and decision-makers in government and health fields.  Scrutiny of rare diseases is vital as there are approximately 7,000 different types of rare diseases and approximately 80 percent are caused by faulty genes [1].  This paper will focus on one, Huntington’s Disease (HD).

This genetic disease is believed to have its origin in Northern Europe [2].  Although HD is found in people of Japanese, Chinese, and African descent, it is still predominantly seen in people of European ancestry.  The United States National Institute of Health (NIH) estimates it affects 3 to 7 per 100,000 people with this ancestry. 

This disease is devastating as symptoms usually appear between the ages of 30 to 50 which are prime income earning and child raising years.  They worsen over a 10 to 25-year timeframe.  Patients can develop personality changes, forgetfulness, impaired judgment, unsteady gait, involuntary movements, slurred speech, difficulty in swallowing and significant weight loss. 

So, what’s the news regarding research to help these patients? Are there any bright lights? Happily, progress is being made as the US FDA approved Teva’s, Austedo (deutrabenazine), in April 2017.  This is only the second drug approved for Huntington’s chorea, a symptom characterized by excessive, involuntary writhing experienced by most HD patients.  This approval provides HD patients with an option in addition to Prestwick Pharmaceuticals’ Xenazine (tetrabenazine) to treat chorea.

Additional good news is seen in a search of Informa’s Trialtrove which shows 30 ongoing and planned trials in HD.   Many of these trials are Phase I–II as seen in Figure 1. These phases comprise 22 of the trials.  This concentration of trials below Phase III is not atypical as many compounds tested do not prove viable in the early phases.

 

 

One Phase II trial of special interest is an open-label extension study evaluating IONIS-HTTRx, a drug seen as having much promise.  In fact, Francis Collins, director of the NIH, recently tweeted, “this is a promising new therapeutic for Huntington’s disease which if shows promise in Phase III clinical trials will be the first drug to directly target the cause of HD” [3]. What a huge milestone as previous drugs approved for HD simply treated symptoms while IONIS-HTTRx moderates the underlying genetic cause of HD by reducing the production of the toxic mutant huntingtin protein (mHTT).  IONIS-HTTRx is an antisense drug designed to reduce the amount of huntingtin RNA in the brain.  Once less RNA message is available, less huntingtin protein is made [4]. Roche showed its belief in the drug’s potential by exercising its option to license this compound from Ionis Pharmaceuticals in December 2017.  This was following the successful completion of the Phase I/IIa study of IONIS-HTTRx in people with HD.  Getting a later start in development is Wave Life Sciences’ WVE-120101 and WVE-120102, which each target a single nucleotide polymorphism (SNP) that marks a separate and distinct location on the mHTT gene transcript. This drug program is the first to target the underlying cause of HD with an allele-specific approach [5].  These programs are in Phase Ib/IIa.

Roche and Wave Life Sciences are two of 18 companies sponsoring planned or ongoing trials in HD.  It is exciting to see strong pharma and biotech interest in this disease. The companies are diverse, ranging in size from Big Pharma, such as Teva and Roche, to the previously mentioned WAVE Life Sciences, a biopharmaceutical firm conducting its first clinical drug program. 

Besides the three drugs by WAVE Life Sciences and Roche targeting the huntingtin protein, many additional targets are being evaluated as seen in Figure 2

 

 

For seven of the drugs, the companies have still not released their targets.  The two drugs which target Vesicular Monoamine Transporter Type 2 (VMAT2), a class of compounds that has demonstrated to have success in treating Central Nervous System movement disorders, such as Huntington’s chorea [6], are Teva’s Xenazine (tetrabenazine) and SOM Biotech’s bevantolol.  While Xenazine is a new compound, bevantolol is an old antihypertensive which is being repurposed to treat Huntington’s chorea. 

The drug for which the target is listed as Not Applicable is Prana Biotechnology’s PBT2.  This drug is designed to interrupt interactions between normally occurring biological metals and target proteins in the brain.   The remaining nine targets are each associated with one drug.  This number of targets might be thought to enhance the odds for success in treating this disease, or as has been seen too frequently with rare diseases, signal the desperation for success as target after target is found unable to provide symptom relief or a cure.  Time will show which is true in this endeavor to relieve symptoms and cure HD.

All in all, the HD clinical trial landscape is dotted with potential. Industry, both large and small, is not ignoring this cruel disease. There are finally drugs being tested which can cure HD rather than solely provide relief of symptoms.  This means there is hope in HD research.  What a cause for celebration if one of these treatments delivers the knock- out punch to Huntington’s Disease! It would be fantastic if there would be one less disease to remember on future Rare Disease Days.  Until then, please do remember Huntington’s disease on February 28, #Rare Disease Day!

 

References

1 Global Genes (2018) Who We Are. Available from: https://globalgenes.org/who-we-are-2/ [Accessed February 21, 2018].

2 Warby, SC et al. (2009) Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup, American Journal of Human Genetics 84:351–366 [Accessed February 21, 2018].

3 Francis Collins (2018) Twitter. Available from:  https://twitter.com/nihdirector/status/941377336271925249  [Accessed February 21, 2018].

4 Huntington’s Disease Society of America (2018) Breaking News:  Update on the Status of the Ionis-HTTRx Program and Its Future. Available from: http://hdsa.org/news/breaking-news-update-on-the-status-of-the-ionis-httrx-program-and-its-future/ [Accessed February 21, 2018].

5 WAVE Life Sciences (2017) Big news in clinical trials for HD! Wave Life Sciences Initiates Two Phase 1/2a Clinical Trials: Prescision-HD1 and Precision-HD2 in Patients with Huntington’s Disease. Available from: http://www.hdfoundation.org/research-news/2017/7/18/big-news-in-clinical-trials-for-hd-wave-life-sciences-initiates-two-phase-1b2a-clinical-trials-precision-hd1-and-precision-hd2-in-patients-with-huntingtons-disease [Accessed February 21, 2018]. 

6 SOM Biotech (2017) Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan). Available from:  http://sombiotech.com/wp-content/uploads/2017/10/NC-and-SOM-Press-Release-Draft-01-Clean_added_PRrev-enviar-RI.pdf [Accessed February 21, 2018].

 

 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: